Cancer News

Different Treatment Options Appear Equally Effective in Early Prostate Cancer (10/03/2016)

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide approximately the same survival rates at 10 years. Spread of cancer, however, was higher among those whose cancer was monitored until progression. These results were recently published … Continue reading "Different Treatment Options Appear Equally Effective in Early Prostate Cancer"

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer (04/25/2016)

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer.  It is important for patients receiving ADT to speak with their healthcare providers if they experience any feelings of depression, as effective treatment … Continue reading "Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer"

Xtandi® Improves Survival in Advanced Prostate Cancer (02/22/2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently published as rapid communication in the Journal of Clinical Oncology. Prostate cancer is the most frequently diagnosed cancer in men … Continue reading "Xtandi® Improves Survival in Advanced Prostate Cancer"